Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06873600 in advanced breast and ovarian cancers
NCT03519178Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Mar 2018
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of ebvaciclib in Hormone-Receptor-Positive Breast Cancer, triple negative breast cancer (TNBC), Epithelial Ovarian Cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Pfizer. Started Mar 2018; status: terminated.
02
Drugs
ebvaciclib
03
Conditions
Hormone-Receptor-Positive Breast Cancertriple negative breast cancer (TNBC)Epithelial Ovarian Cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03519178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03519178.